Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials

Abstract excerpt

An increasing awareness of the disease, new diagnostic tools and novel therapeutic opportunities have dramatically changed the management of patients with amyloid transthyretin cardiomyopathy (ATTR-CM). Supportive therapies have shown limited benefits, mostly related to diuretics for the relief from signs and symptoms of congestion in patients presenting heart failure (HF). On the other hand, huge advances in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Amyloidosis: Diagnosis, Treatment, Outcomes
• Share to Cardiomyopathy and Myosin Studies
• Share to Peptidase Inhibition and Analysis